These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28131405)

  • 1. Selection of the Best of 2016 in Diabetes and Heart.
    Cosín-Sales J; Escobar C; Marzal D; Barrios V
    Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):124-125. PubMed ID: 28131405
    [No Abstract]   [Full Text] [Related]  

  • 2. Selection of the Best of 2016 in Vascular Risk and Cardiac Rehabilitation.
    Castro Conde A; Campuzano Ruiz R; Morillas Bueno M; Arrarte Esteban V; Berenguel Senén A; Abeytua M
    Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):128-129. PubMed ID: 28131408
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials.
    Holman RR
    Nat Rev Endocrinol; 2018 Feb; 14(2):67-68. PubMed ID: 29302077
    [No Abstract]   [Full Text] [Related]  

  • 4. The global challenge of diabetes.
    Lancet; 2008 May; 371(9626):1723. PubMed ID: 18502275
    [No Abstract]   [Full Text] [Related]  

  • 5. Legacy effect in medicine-the expanding horizon!
    Wander GS; Bansal M
    Indian Heart J; 2018; 70(6):769-771. PubMed ID: 30580842
    [No Abstract]   [Full Text] [Related]  

  • 6. [A search for novel pathways of effective prevention of cardiovascular complications in patients with type 2 diabetes mellitus: advance trial].
    Karpov IuA; Shubina AT
    Kardiologiia; 2007; 47(10):90-5. PubMed ID: 18260953
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular safety of incretin-based therapy for type 2 diabetes: A meta-analysis of randomized trials.
    Mahmoud AN; Saad M; Mansoor H; Elgendy AY; Barakat AF; Abuzaid A; Mentias A; Elgendy IY
    Int J Cardiol; 2017 Mar; 230():324-326. PubMed ID: 28043676
    [No Abstract]   [Full Text] [Related]  

  • 8. In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(5):410. PubMed ID: 26926979
    [No Abstract]   [Full Text] [Related]  

  • 9. Arresting cardiovascular disease progression. Early treatment may counteract high risk.
    Ram CV; Vergne-Marini P
    Postgrad Med; 2004 Aug; 116(2):45-8. PubMed ID: 15323153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could clinical inertia in part explain the unexpected association of insulin therapy with poorer cardiovascular outcomes in observational studies on diabetes?
    Giorda CB
    Diabetes Res Clin Pract; 2011 Jun; 92(3):e47-8. PubMed ID: 21035888
    [No Abstract]   [Full Text] [Related]  

  • 11. Emerging strategies for diabetes and cardiovascular disorders: Introduction and foreword.
    Deedwania P
    Prog Cardiovasc Dis; 2019; 62(4):295-297. PubMed ID: 31469996
    [No Abstract]   [Full Text] [Related]  

  • 12. Diabetes management: More than just cardiovascular risk?
    Zimmerman RS; Pantalone KM
    Cleve Clin J Med; 2014 Nov; 81(11):672-6. PubMed ID: 25368217
    [No Abstract]   [Full Text] [Related]  

  • 13. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
    Laakso M
    Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
    [No Abstract]   [Full Text] [Related]  

  • 14. [Advances in diabetes mellitus, diabetic nephropathy, metabolic syndrome and cardio-vascular-renal risk].
    Martínez Castelao A
    Nefrologia; 2008; 28 Suppl 5():79-84. PubMed ID: 18847425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Primary prevention of diabetes mellitus type 2].
    Gallwitz B
    Internist (Berl); 2004 Jun; 45 Suppl 1():S15-22. PubMed ID: 15241504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety trials: be careful what you wish for.
    Bloomgarden Z; Grunberger G
    J Diabetes; 2014 Jan; 6(1):1-3. PubMed ID: 24103189
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anti-diabetic therapy and cardiovascular risk].
    Mannucci E
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):3S. PubMed ID: 25623544
    [No Abstract]   [Full Text] [Related]  

  • 18. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
    Ametov AS; P'ianykh OP; Chernikova NA
    Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focus on metformin - a major cardiovascular medication. 'Diabesity - the biggest epidemic in human history'.
    Straughan JL
    Cardiovasc J Afr; 2007; 18(5):331-3. PubMed ID: 17985034
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist.
    Wikström G; Malmberg K; Rydén L
    Eur Heart J; 1999 Mar; 20(6):403-5. PubMed ID: 10213343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.